Mexico sees progress in talks to revise USMCA, says drug protections to ease
Reuters
Published Dec 04, 2019 03:34PM ET
Mexico sees progress in talks to revise USMCA, says drug protections to ease
By David Lawder
WASHINGTON (Reuters) - Mexico's government said on Wednesday that progress was being made toward revising a new North American trade pact, and that protections for biologic drugs will be sharply reduced under it, in what would be a setback for U.S. pharmaceutical companies.
Mexico approved the United States-Mexico-Canada Agreement (USMCA) earlier this year, but U.S. ratification has been held up by Democratic lawmakers pressing the Trump administration to make changes to the deal, including on drug protections.
Following nearly four hours of talks with U.S. Trade Representative Robert Lighthizer in Washington, Mexico's top negotiator for the USMCA, Deputy Foreign Minister Jesus Seade, said he believed a deal was closer than it had been.
He told reporters there were still two or three tough questions that needed to be resolved, floating the possibility of thrashing out an accord in the coming days.
"But there are things we can't accept," he said.
Among the most contentious issues under discussion is how to ensure that Mexico raises its labor standards.
Democrats have pressed to get stricter enforcement of new Mexican labor rules enshrined in the deal by proposing that inspectors supervise their implementation.
Mexico has firmly rejected that proposal, although Seade said last week that tweaks could be made to how labor disputes are handled to facilitate an accord.
Separately, in a column for Mexican newspaper El Universal, Seade said "very high protection" for biologic drugs will be "eased drastically" in changes under discussion for the USMCA.
Seade said he could not provide more details for now on the modifications. But U.S. Democratic lawmakers have described as a "giveaway" a provision under USMCA that would grant 10 years of data exclusivity for makers of biologic medicines, arguing that it will lead to higher prices for consumers.
Kenneth Smith, who was Mexico's principal USMCA negotiator from 2017 to 2018, told Reuters that Democrats were pressing to eliminate biologic protections for drug makers.
If the USMCA provision were simply cut, rules could revert to the considerably thinner protections of the 1994 North American Free Trade Agreement (NAFTA), he said. Or, new language could be agreed as a compromise, Smith added.
Mexican business groups have bristled against the Democratic labor market plan as an attempt to make the country less attractive to investment, and President Andres Manuel Lopez Obrador said on Tuesday Mexico would not accept it.
In the column, Seade said there would be no inspectors.
The USMCA is due to replace NAFTA, which U.S. President Donald Trump threatened to scrap if it was not overhauled.
Get The News You Want
Seade said in his column that existing flaws in NAFTA's dispute resolution mechanisms would be fixed in the adjustments currently being made to USMCA.
He told reporters in Washington he had held meetings through the weekend in Mexico with Lopez Obrador and business groups to address outstanding USMCA issues.
Speaking in Mexico City, Carlos Salazar, the head of Mexico's powerful CCE business lobby, said he was hopeful that Seade could broker an agreement before Dec. 20. Failing that, there could still be a deal in early January, he said.
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.